|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
|
|---|---|---|---|---|---|---|
| Cash | ||||||
| Cash and cash equivalents | ||||||
| Due from Sponsor | ||||||
| Prepaid insurance current | ||||||
| Total current assets | ||||||
| Deferred offering costs associated with proposed public offering | ||||||
| Investments held in Trust Account | ||||||
| Prepaid insurance | ||||||
| Total Assets | ||||||
| Accrued offering expenses | ||||||
| Accounts payable and accrued expenses | ||||||
| Due to related party | ||||||
| Due to sponsor | ||||||
| Total current liabilities | ||||||
| Deferred underwriting commission | ||||||
| Total liabilities | ||||||
| Commitments and Contingencies | ||||||
| Class A ordinary shares subject to possible redemption, 27,600,000 and 27,600,000 shares issued and outstanding at redemption value of $10.53 and $10.35 per share as of June 30, 2026 and December 31, 2025, respectively | ||||||
| Shareholders’ Deficit | ||||||
| Ordinary shares, value issued | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Total shareholders’ deficit | ||||||
| Total Liabilities and Shareholders’ Deficit |
Loading...
